Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Update: 2025-09-15
Description
Host: Marlene Mimi Maeusli, PhD.
A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. Mimi Maeusli explains how this evidence is reshaping our view of ibrutinib's clinical utility.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
